Dr. Bendell Discusses Pembrolizumab in CRC
In Partnership With:
Johanna C. Bendell, MD, medical oncologist, Sarah Cannon Research Institute, discusses pembrolizumab (Keytruda) in colorectal cancer.
Johanna C. Bendell, MD, medical oncologist, Sarah Cannon Research Institute, discusses pembrolizumab (Keytruda) in colorectal cancer (CRC).
Pembrolizumab is currently approved for any patient with a microsatellite instable tumors, including CRC. This is the first time that the FDA has approved an agent based on a biomarker, as opposed to a tumor type, says Bendell.
Related Videos
Related Content
